Categories
All News

Cancer/Tumor Profiling Market Continues Rapid Growth | QIAGEN N.V., NeoGenomics Laboratories, Inc., HTG Molecular Diagnostics, Inc., Genomic Health Inc., Caris Life Sciences, Helomics Corporation

The Cancer/Tumor Profiling Market report puts forth an array of market insights that help with more precise understanding of the market landscape, issues that may impose on the industry in the future, and how to position-specific brands in the best way. Today’s businesses call for greatly focused, widespread and detail-oriented market information so that the idea about the market landscape is absolutely clear. The Cancer/Tumor Profiling Market research report has been produced with a combination of in-depth industry insights and the newest tools and technologies. The market research analysis report is really a backbone for every business that wishes to boom in the market.

Global cancer/tumor profiling market size is projected to reach USD 13.9 billion by 2025 from USD 8.3 billion in 2020, at a CAGR of 10.9 %. Factors such as the increasing incidence of cancer, increasing demand for personalized medicine, increasing use of biomarkers in cancer profiling, increasing cancer research and funding, and technological advancements in the field are expected to drive the growth of cancer/tumor profiling market. However, poor regulatory and reimbursement scenario serves as a major challenge for the industry.

Request for FREE PDF Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=268825

Key players in cancer/tumor profiling market

The key players operating in cancer/tumor profiling market include Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Holdings Inc. (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq (US), Histogene X (Belgium).

By technology, the next generation sequencing segment holds the highest market share during the forecast period.

Based on technology, the cancer/tumor profiling market is segmented into immunoassays, in situ hybridization, next generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and others. The immunoassays segment held the highest market share in 2019. The high market share of this segment can be attributed to the wide adoption of these assays as it is the gold standard to measure the presence and concentration of analytes in a sample.

Based on cancer type, the lung cancer segment is expected to register the highest CAGR during the forecast period.

Based on cancer type, the cancer/tumor profiling market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and others. The lung cancer segment is projected to register the highest CAGR during the forecast period. The significant growth in the lung cancer is attributed to the high incidence rate of lung cancer and the increasing need for early diagnosis.

By biomarker type, the genetic biomarker segment holds the highest market share during the forecast period.

Based on biomarker type, the cancer/tumor profiling market is segmented genetic biomarkers, protein biomarkers, and other biomarkers. The genetic segment held the highest market share in 2019. The high market share of this segment can be attributed to the high adoption of these biomarkers during cancer diagnosis and prognosis and in the biomarker discovery process.

By application type, the research application segment holds the highest market share during the forecast period.

Based on cancer type, the cancer/tumor profiling market is segmented research and clinical applications. The research application segment held the highest market share in 2019. The high market share of this segment can be attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the increased funding for cancer research is propelling the growth of the market.

By Region, The Asia Pacific region holds the highest market share during the forecast period.

The Asia Pacific holds the highest market share during the forecast period (2020 to 2025).

Rapidly incidence of cancer, growing proteomics and genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries, are supporting the growth of the cancer/tumor market in the Asia Pacific region.

Break of primary participants was as mentioned below:

  • By Company Type – Tier 1–35%, Tier 2–45% and Tier 3–20%
  • By Designation – C-level–35%, D-level–25%, Others–40%
  • By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, Middle East and Africa–2%

Research Coverage:

The report analyzes the cancer/tumor profiling market and aims at estimating the market size and future growth potential of this market based on various segments such as product, distribution channel, and region. The report also includes a product portfolio matrix of various cancer profiling products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes this market by product and distribution channel.
  • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global cancer/tumor profiling market
  • Market Development:Comprehensive information on the lucrative emerging markets by product and distribution channel
  • Market Diversification:Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global cancer/tumor profiling market
  • Competitive Assessment:In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global cancer/tumor profiling market.

Get Discount on the Latest Report @ https://www.reportsnreports.com/contacts/discount.aspx?name=268825

Table Of Contents

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition & Scope
1.2.1 Markets Covered
Figure 1 Cancer/Tumor Profiling Market
1.2.2 Years Considered For The Study
1.3 Currency
1.4 Stakeholders
1.5 Limitations
1.6 Summary Of Changes

2 Research Methodology
2.1 Research Approach
Figure 2 Research Design
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown Of Primaries
Figure 3 Breakdown Of Primary Interviews: By Company Type, Designation, And Region
2.1.2.3 Key Industry Insights
2.2 Market Sizing & Validation Approach
Figure 4 Segmental Share Analysis Illustration
Figure 5 Top-Down Approach
2.3 Data Triangulation Approach
Figure 6 Data Triangulation Methodology
2.4 Assumptions For The Study

3 Executive Summary
Figure 7 Cancer/Tumor Profiling Market, By Technology, 2020 Vs. 2025 (Usd Million)
Figure 8 Cancer/Tumor Profiling Market, By Cancer Type, 2020 Vs. 2025 (Usd Million)
Figure 9 Cancer/Tumor Profiling Market, By Biomarker Type, 2020 Vs. 2025 (Usd Million)
Figure 10 Cancer/Tumor Profiling Market, By Application, 2020 Vs. 2025 (Usd Million)
Figure 11 Geographical Snapshot Of The Cancer/Tumor Profiling Market

4 Premium Insights
4.1 Cancer/Tumor Profiling: Market Overview
Figure 12 Increasing Demand For Personalized Medicine To Drive Market Growth
4.2 Cancer/Tumor Profiling Market: Geographic Growth Opportunities
Figure 13 China To Register The Fastest Growth In The Cancer/ Tumor Profiling Market During The Forecast Period
4.3 Regional Mix: Cancer/Tumor Profiling Market (2020-2025)
Figure 14 Apac To Witness The Fastest Growth During The Forecast Period (2020-2025)
4.4 Cancer/Tumor Profiling Market: Developed Vs. Developing Markets (2020 Vs. 2025)
Figure 15 Developing Markets To Register A Higher Growth Rate Between 2020 & 2025

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 16 Cancer/Tumor Profiling Market: Drivers, Restraints, Opportunities, And Challenges
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence Of Cancer
Figure 17 Global Cancer Incidence, 2008-2030
5.2.1.2 Increasing Use Of Biomarkers In Cancer Profiling
5.2.1.3 Increasing Cancer Research And Funding
5.2.1.4 Technological Advancements
Table 1 Market Drivers: Impact Analysis
5.2.2 Market Restraints
5.2.2.1 High Capital Investment
5.2.2.2 Technical Issues With Sample Collection And Storage
Table 2 Market Restraints: Impact Analysis
5.2.3 Market Opportunities
5.2.3.1 Increasing Demand For Personalized Medicine
Figure 18 Launch Of Personalized Medicine Products, 2008-2016
5.2.3.2 Growing Need For Point-Of-Care Diagnostics
Table 3 Market Opportunities: Impact Analysis
5.2.4 Market Challenges
5.2.4.1 Low Biomarker Discovery-To-Approval Ratio
5.2.4.2 Poor Regulatory And Reimbursement Scenario
Table 4 Market Challenges: Impact Analysis

6 Industry Insights
6.1 Introduction
6.2 Industry Trends
Figure 19 Increasing Use Of Integrated Omics Data And Growing Focus On Liquid Biopsy Tests Are Key Market Trends
6.2.1 Integration Of Omics Data
6.2.2 Advances In Liquid Biopsy
6.2.3 Organoids For Personalized Medicine
6.3 Covid-19 Impact On The Cancer/Tumor Profiling Market
Figure 20 Impact Of Covid-19 On The Cancer/Tumor Profiling Market

7 Cancer/Tumor Profiling Market, By Technology
7.1 Introduction
7.2 Covid-19 Impact, By Technology
Figure 21 Immunoassays To Dominate The Cancer/Tumor Profiling Market During The Forecast Period
Table 5 Cancer/Tumor Profiling Market, By Technology, 2017-2019 (Usd Million)
Table 6 Cancer/Tumor Profiling Market, By Technology, 2020-2025 (Usd Million)
7.3 Immunoassays
7.3.1 Immunoassay Tests Identify And Assess The Progression Of Disease, Thereby Providing Information Vital For Better Therapeutic Choices
Table 7 Cancer/Tumor Profiling Market For Immunoassays, By Country/Region, 2017-2019 (Usd Million)
Table 8 Cancer/Tumor Profiling Market For Immunoassays, By Country/Region, 2020-2025 (Usd Million)
7.4 Next Generation Sequencing
7.4.1 Advances In Ngs Multiplexing Capabilities Enable One Assay To Provide A Complete Tumor Molecular Profile
Table 9 Cancer/Tumor Profiling Market For Next Generation Sequencing, By Country/Region, 2017-2019 (Usd Million)
Table 10 Cancer/Tumor Profiling Market For Next Generation Sequencing, By Country/Region, 2020-2025 (Usd Million)
7.5 Polymerase Chain Reaction
7.5.1 Real-Time Pcr Helps In The Quantification Of Low-Copy Transcripts, Aiding Biomarker Identification
Table 11 Cancer/Tumor Profiling Market For Polymerase Chain Reaction, By Country/Region, 2017-2019 (Usd Million)
Table 12 Cancer/Tumor Profiling Market For Polymerase Chain Reaction, By Country/Region, 2020-2025 (Usd Million)
7.6 In Situ Hybridization
7.6.1 Fish Is The Gold Standard For Evaluating Some Key Biomarkers And Plays A Critical Role In Guiding Targeted Therapies
Table 13 Cancer/Tumor Profiling Market For In Situ Hybridization, By Country/Region, 2017-2019 (Usd Million)
Table 14 Cancer/Tumor Profiling Market For In Situ Hybridization, By Country/Region, 2020-2025 (Usd Million)
7.7 Microarrays
7.7.1 Microarrays Are Widely Adopted In Diagnostics As They Aid In Predicting The Recurrence Of Cancer After Treatment
Table 15 Cancer/Tumor Profiling Market For Microarrays, By Country/Region, 2017-2019 (Usd Million)
Table 16 Cancer/Tumor Profiling Market For Microarrays, By Country/Region, 2020-2025 (Usd Million)
7.8 Mass Spectrometry
7.8.1 Technological Advancements Are Supporting The Adoption Of This Technology For Sensitive, Reliable, And Rapid Diagnosis
Table 17 Cancer/Tumor Profiling Market For Mass Spectrometry, By Country/Region, 2017-2019 (Usd Million)
Table 18 Cancer/Tumor Profiling Market For Mass Spectrometry, By Country/Region, 2020-2025 (Usd Million)
7.9 Other Technologies
Table 19 Cancer/Tumor Profiling Market For Other Technologies, By Country/Region, 2017-2019 (Usd Million)
Table 20 Cancer/Tumor Profiling Market For Other Technologies, By Country/Region, 2020-2025 (Usd Million)

8 Cancer/Tumor Profiling Market, By Cancer Type
8.1 Introduction
Figure 22 Breast Cancer Segment To Dominate The Cancer/Tumor Profiling Market During The Forecast Period
Table 21 Cancer/Tumor Profiling Market, By Cancer Type, 2017-2019 (Usd Million)
Table 22 Cancer/Tumor Profiling Market, By Cancer Type, 2020-2025 (Usd Million)
8.2 Breast Cancer
8.2.1 Breast Cancer Is The Most Common Cancer Found Among Women
Table 23 Cancer/Tumor Profiling Market For Breast Cancer, By Country/Region, 2017-2019 (Usd Million)
Table 24 Cancer/Tumor Profiling Market For Breast Cancer, By Country/Region, 2020-2025 (Usd Million)
8.3 Lung Cancer
8.3.1 Molecular Characterization Of Tumors Using Ngs Is A Key Tool For The Clinical Management Of Nsclc Patients
Figure 23 Global Lung Cancer Incidence, 2012-2030
Table 25 Cancer/Tumor Profiling Market For Lung Cancer, By Country/Region, 2017-2019 (Usd Million)
Table 26 Cancer/Tumor Profiling Market For Lung Cancer, By Country/Region, 2020-2025 (Usd Million)
8.4 Colorectal Cancer
8.4.1 Ihc, Pcr, Microarrays, And Imaging Technologies Are Major Technologies Used In Colorectal Diagnostics
Figure 24 Colorectal Cancer Incidence Rate, Key Countries (2018)
Table 27 Cancer/Tumor Profiling Market For Colorectal Cancer, By Country/Region, 2017-2019 (Usd Million)
Table 28 Cancer/Tumor Profiling Market For Colorectal Cancer, By Country/Region, 2020-2025 (Usd Million)
8.5 Prostate Cancer
8.5.1 Prostate-Specific Antigen Is A Widely Used Fda-Approved Biomarker For Prostate Cancer Screening
Table 29 Cancer/Tumor Profiling Market For Prostate Cancer, By Country/Region, 2017-2019 (Usd Million)
Table 30 Cancer/Tumor Profiling Market For Prostate Cancer, By Country/Region, 2020-2025 (Usd Million)
8.6 Melanoma
8.6.1 Rt-Qpcr Is Generally Utilized To Conduct Molecular Profiling And Analyze Biomarkers In Melanomas
Table 31 Cancer/Tumor Profiling Market For Melanoma, By Country/Region, 2017-2019 (Usd Million)
Table 32 Cancer/Tumor Profiling Market For Melanoma, By Country/Region, 2020-2025 (Usd Million)
8.7 Other Cancers
Table 33 Cancer/Tumor Profiling Market For Other Cancers, By Country/Region, 2017-2019 (Usd Million)
Table 34 Cancer/Tumor Profiling Market For Other Cancers, By Country/Region, 2020-2025 (Usd Million)

9 Cancer/Tumor Profiling Market, By Biomarker Type

Read More…………..

About Us:

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact Us:

Corporate Headquarters

Tower B5, office 101,
Magarpatta SEZ,
Hadapsar, Pune-411013, India

 + 1 888 391 5441
 [email protected]

https://jumbonews.co.uk/